Passage Bio, Inc. (PASG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Passage Bio, Inc. (PASG) Healthcare & Pipeline Overview

Passage Bio, Inc. is a clinical-stage genetic medicines company targeting central nervous system disorders through innovative AAV-delivered gene therapies. With a focus on diseases like GM1 gangliosidosis and frontotemporal dementia, Passage Bio leverages strategic collaborations to advance its pipeline and address unmet medical needs in the biotechnology sector.

What Is the Investment Thesis for PASG?

Passage Bio presents a high-risk, high-reward investment opportunity within the genetic medicines space. The company's focus on rare CNS disorders offers the potential for significant revenue generation if its gene therapy candidates are successfully developed and approved. Key value drivers include the clinical progress of PBGM01 for GM1 gangliosidosis and PBFT02 for FTD-GRN. Upcoming clinical trial data releases will be critical catalysts. However, the company faces significant challenges, including the inherent risks associated with gene therapy development, regulatory hurdles, and the need for substantial capital to fund ongoing research and clinical trials. The current market capitalization of $14.4M reflects the early stage of the company and the uncertainties associated with its pipeline.

Based on FMP financials and quantitative analysis

PASG Key Highlights

Passage Bio focuses on developing gene therapies for rare central nervous system disorders, addressing significant unmet medical needs.

• The company's lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for FTD-GRN, are in clinical development, with upcoming data readouts being key milestones.
• Passage Bio leverages a proprietary AAV capsid, AAVhu68, for targeted gene delivery to the brain and peripheral tissues.
• Strategic collaborations with the University of Pennsylvania's Gene Therapy Program and Catalent Maryland provide access to expertise and manufacturing capabilities.
• The company's market capitalization of $14.4M reflects its early stage and the inherent risks associated with gene therapy development.

Who Are PASG's Competitors?

PASG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PASG's Key Strengths?

Proprietary AAVhu68 capsid technology for targeted gene delivery.

• Focus on rare CNS disorders with high unmet medical needs.
• Strategic collaborations with leading academic institutions.
• Experienced management team with expertise in gene therapy development.

What Are PASG's Weaknesses?

Early-stage company with limited revenue and a high cash burn rate.

• Dependence on the success of its lead programs, PBGM01 and PBFT02.
• High regulatory and manufacturing hurdles associated with gene therapy development.
• Competition from larger pharmaceutical companies and other biotech firms in the gene therapy space.

What Could Drive PASG Stock Higher?

Data readout from Phase 1/2 clinical trial of PBGM01 for GM1 gangliosidosis.

• Initiation of Phase 1/2 clinical trial of PBFT02 for FTD-GRN.
• Enrollment of patients in ongoing clinical trials.
• Advancement of preclinical programs for other CNS disorders.

What Are the Key Risks for PASG?

Financial-distress signal — its Altman Z-Score of -43.80 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of its gene therapy candidates.
• Competition from other gene therapy companies.
• Adverse events or safety concerns associated with its gene therapy products.
• Dependence on securing additional funding to support its research and development efforts.

What Are the Growth Opportunities for PASG?

• Expansion into New Therapeutic Areas: Passage Bio has the opportunity to leverage its AAV gene therapy platform to expand its pipeline into additional CNS disorders. This could involve targeting new genetic mutations or exploring different delivery routes. The market for CNS therapeutics is substantial, with a global market size estimated at over $100 billion. This expansion could diversify Passage Bio's portfolio and reduce its reliance on its current lead programs. Timeline: Ongoing, with potential new program announcements in the next 1-3 years.
• Advancement of PBGM01 for GM1 Gangliosidosis: PBGM01 represents a significant growth opportunity for Passage Bio. Positive clinical trial data could lead to regulatory approval and commercialization, addressing a critical unmet need for patients with GM1 gangliosidosis. The market for GM1 gangliosidosis therapies is estimated to be relatively small due to the rarity of the disease, but the high price point of gene therapies could generate substantial revenue. Timeline: Near-term, with potential for regulatory submission within the next 2-3 years.
• Development of PBFT02 for FTD-GRN: PBFT02 targets frontotemporal dementia (FTD) caused by GRN gene mutations, a significant unmet medical need. Successful development and commercialization of PBFT02 could provide a valuable treatment option for patients with this devastating neurodegenerative disease. The market for FTD therapies is expected to grow as the population ages and diagnostic tools improve. Timeline: Mid-term, with clinical trials ongoing and potential for regulatory submission in the next 3-5 years.
• Strategic Partnerships and Collaborations: Passage Bio can continue to leverage strategic partnerships and collaborations to advance its research and development efforts. Collaborations with academic institutions, such as the University of Pennsylvania, and contract manufacturing organizations, such as Catalent, can provide access to expertise, resources, and manufacturing capabilities. These partnerships can accelerate the development of Passage Bio's pipeline and reduce its overall risk. Timeline: Ongoing, with potential for new partnership announcements in the coming years.
• Expansion of AAVhu68 Capsid Technology: Passage Bio's proprietary AAVhu68 capsid technology offers a potential competitive advantage in gene therapy delivery. The company can explore expanding the applications of this technology to other CNS disorders or licensing it to other companies. This could generate additional revenue streams and further validate the value of Passage Bio's technology platform. Timeline: Long-term, with ongoing research and development efforts to optimize and expand the applications of AAVhu68.

What Are PASG's Competitive Advantages?

• Proprietary AAV capsid technology (AAVhu68) for targeted gene delivery to the brain and peripheral tissues.
• Focus on rare CNS disorders with limited treatment options.
• Strategic collaborations with leading academic institutions and contract manufacturing organizations.
• Intellectual property protection for their gene therapy candidates and technologies.

What Does PASG Do?

Passage Bio, Inc. is a genetic medicines company founded in 2017 and headquartered in Philadelphia, Pennsylvania. The company is dedicated to developing transformative therapies for central nervous system (CNS) disorders, an area of significant unmet medical need. Passage Bio's approach centers on utilizing adeno-associated virus (AAV) vectors to deliver functional genes to the brain and peripheral tissues, aiming to correct the underlying genetic causes of these diseases. The company's pipeline includes several gene therapy candidates. PBGM01 is being developed for infantile GM1 gangliosidosis, a rare and fatal lysosomal storage disorder. PBFT02 targets frontotemporal dementia (FTD) caused by granulin (GRN) gene mutations. PBKR03 is in development for infantile Krabbe disease, another devastating lysosomal storage disorder. Additional programs include PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis (ALS), and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio collaborates with the Gene Therapy Program at the University of Pennsylvania, leveraging their expertise in gene therapy research and development. The company also has agreements with Catalent Maryland, Inc. for development services and clinical supply. Passage Bio's focus on rare CNS diseases and its strategic partnerships position it to potentially deliver innovative therapies to patients with limited treatment options.

What Products and Services Does PASG Offer?

• Develop gene therapies for central nervous system (CNS) disorders.
• Utilize adeno-associated virus (AAV) vectors to deliver functional genes to the brain and peripheral tissues.
• Focus on rare genetic diseases with significant unmet medical needs.
• Develop PBGM01 for infantile GM1 gangliosidosis.
• Develop PBFT02 for frontotemporal dementia (FTD) caused by GRN gene mutations.
• Develop PBKR03 for infantile Krabbe disease.
• Conduct preclinical and clinical trials to evaluate the safety and efficacy of their gene therapy candidates.
• Collaborate with academic institutions and contract manufacturing organizations to advance their research and development efforts.

How Does PASG Make Money?

• Develop and commercialize gene therapies for rare CNS disorders.
• Generate revenue through the sale of approved gene therapy products.
• Out-license their AAV capsid technology to other companies.
• Collaborate with pharmaceutical companies for co-development and commercialization of gene therapies.

What Industry Does PASG Operate In?

Passage Bio operates within the rapidly evolving biotechnology industry, specifically in the genetic medicines and gene therapy sector. This sector is characterized by high growth potential, driven by advancements in gene editing and delivery technologies, but also faces significant regulatory and manufacturing challenges. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms focused on gene therapy development. Passage Bio's focus on rare CNS disorders differentiates it from companies targeting more prevalent diseases.

Who Are PASG's Key Customers?

• Patients with rare CNS disorders, such as GM1 gangliosidosis, FTD-GRN, and Krabbe disease.
• Hospitals and clinics that treat patients with these disorders.
• Physicians who specialize in neurology and genetics.
• Pharmaceutical companies that may partner with Passage Bio to co-develop and commercialize gene therapies.

Wall Street analysts project Passage Bio, Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-8.63. The estimate reflects 4 contributing analysts.

PASG Valuation & Market Position

With a $14.4M market cap, Passage Bio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PASG's quantitative score of 31/100 is below the peer average of 67/100.

Key Financial Metrics

A current ratio of 1.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -199.9%, the inverse of the P/E and a quick read on earnings relative to price.

Passage Bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -43.80 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Passage Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO William Chou. PASG has traded publicly since 2020.

PASG Financials

PASG Latest News

PASG Analyst Consensus

PASG MoonshotScore

What Investors Ask About Passage Bio, Inc. (PASG) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources